Companies / United States
BMS Leaves ImClone To Lilly
October 2008 | Company News AlertDemonstrating the importance that big pharma is placing on a strong pipeline as it heads into the patent cliff, Eli Lilly has gazumped rival suitor Bristol-Myers Squibb (BMS) with a US$6.5bn, US$70 a share, bid for innovative biotechnology company ImClone Systems. The deal is expected to close in late 2008 or early
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
